← All Market Monitors SANOR About SANOR
GLP-1 Market MonitorDeal activity

Revvity to Acquire Human Cell Design, Expanding Its Metabolic-Disease Research Tools

Updated 20 September 2026

What Is Happening

Revvity agreed to acquire Human Cell Design, a provider of human-relevant cell models used in metabolic-disease research. The acquisition would add research tools used in diabetes and obesity programs, including GLP-1 drug discovery.

Financial terms were not disclosed in the company announcement.

Closing is expected in the fourth quarter of 2026.

The transaction remains subject to regulatory approvals and other customary closing conditions.

Sources (1)

Companies Involved

Revvity

Life sciences company

Revvity supplies tools and services for life sciences research and diagnostics.

Mentioned In

GLP-1 Market Monitor

Updated 6 days ago

Ticker activity
$79.0bnAnnual market size
9.17%Forecast annual growth (CAGR)2025–2035

Active companies

Free Playbook

The Private Clinic Playbook

Grow revenue at each location and build a commercial model that can scale across a clinic group.

Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.

Privacy Policy Terms of Service Disclaimer Sitemap

SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.

SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.

All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.

© 2026 SANOR Intelligence